ASCO 2024 Abstract for Trial #22-09

A phase 1a/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas.

Wednesday, June 19, 2024

Dr. Minal Barve

Read the Story Here

Click the above link to view the abstract.

ASCO 2024 Poster for Trial 22-09

ASCO 2024 Poster for Trial 22-09

Click here to view the ASCO 2024 Poster for Trial 22-09 in Full-Size.

Related Abstracts

Discover more abstracts for our trials.

First-in-human Phase 1/2a Trial of a Macrocyclic ATR inhibitor (ATRN-119) in Patients with Advanced Solid Tumors.

Oct 2, 2024

Dr. Reva Schneider

Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors

Sep 24, 2024

Dr. Reva Schneider

First-in-human results of STX-478, a mutant-selective PI3Kα inhibitor, in advanced solid tumor patients

Sep 24, 2024

Dr. Douglas Orr
See All Posts